Web NewDrugInformation.com

Panretin Drug - Panretin The trade name of the product as shown on the labeling. Dosage - GEL; TOPICAL The product dosage form and route separated by a semi-colon. Active Ingredient(s) - Alitretinoin Multiple ingredients are in alphabetical order. Strength - EQ 0.1% BASE The potency of the active ingredient(s), Alitretinoin. May repeat for multiple part products. Applicant - LIGAND The firm name holding legal responsibility for Panretin. The firm name is condensed to a maximum twenty character unique string. New Drug Application (NDA) Number - 020886 The FDA assigned number to Panretin. Format is nnnnnn. Product Number - 001 The FDA assigned number to identify Panretin. Each strength is a separate product. May repeat for multiple part products. Format is nnn. Therapeutic Equivalence (TE) Code - The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products. Approval Date - Feb 2, 1999 The date Panretin was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982". Reference Listed Drug (RLD) - Yes The pioneer or innovator of Panretin. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No. Type - RX The group or category of approved drugs Panretin is in. Format is RX, OTC, DISCN. Applicant Full Name - Ligand Pharmaceuticals Inc The full name of the firm holding legal responsibility for the new application of Panretin. Panretin Fosamax Eq 70mg Base Tablet; Oral Fosamax Plus D Eq 70mg Base;2,800 Iu Tablet; Oral Alfenta Eq 0.5mg Base/ml Injectable; Injection Alfentanil Eq 0.5mg Base/ml Injectable; Injection Uroxatral 10mg Tablet, Extended Release; Oral Ceredase 10 Units/ml Injectable; Injection Ceredase 80 Units/ml Injectable; Injection Panretin Eq 0.1% Base Gel; Topical Fosamax Eq 40mg Base Tablet; Oral Fosamax Eq 5mg Base Tablet; Oral NewDrugInformation